BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

247 related articles for article (PubMed ID: 16809801)

  • 1. Time-dependent interaction between lopinavir/ritonavir and fexofenadine.
    van Heeswijk RP; Bourbeau M; Campbell P; Seguin I; Chauhan BM; Foster BC; Cameron DW
    J Clin Pharmacol; 2006 Jul; 46(7):758-67. PubMed ID: 16809801
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Different effects of three transporting inhibitors, verapamil, cimetidine, and probenecid, on fexofenadine pharmacokinetics.
    Yasui-Furukori N; Uno T; Sugawara K; Tateishi T
    Clin Pharmacol Ther; 2005 Jan; 77(1):17-23. PubMed ID: 15637527
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of an antiretroviral regimen containing ritonavir boosted lopinavir on intestinal and hepatic CYP3A, CYP2D6 and P-glycoprotein in HIV-infected patients.
    Wyen C; Fuhr U; Frank D; Aarnoutse RE; Klaassen T; Lazar A; Seeringer A; Doroshyenko O; Kirchheiner JC; Abdulrazik F; Schmeisser N; Lehmann C; Hein W; Schömig E; Burger DM; Fätkenheuer G; Jetter A
    Clin Pharmacol Ther; 2008 Jul; 84(1):75-82. PubMed ID: 18183034
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lack of dose-dependent effects of itraconazole on the pharmacokinetic interaction with fexofenadine.
    Uno T; Shimizu M; Sugawara K; Tateishi T
    Drug Metab Dispos; 2006 Nov; 34(11):1875-9. PubMed ID: 16928786
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of Ginkgo biloba extract on lopinavir, midazolam and fexofenadine pharmacokinetics in healthy subjects.
    Robertson SM; Davey RT; Voell J; Formentini E; Alfaro RM; Penzak SR
    Curr Med Res Opin; 2008 Feb; 24(2):591-9. PubMed ID: 18205997
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lopinavir/ritonavir reduces bupropion plasma concentrations in healthy subjects.
    Hogeland GW; Swindells S; McNabb JC; Kashuba AD; Yee GC; Lindley CM
    Clin Pharmacol Ther; 2007 Jan; 81(1):69-75. PubMed ID: 17186001
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of grapefruit juice volume on the reduction of fexofenadine bioavailability: possible role of organic anion transporting polypeptides.
    Dresser GK; Kim RB; Bailey DG
    Clin Pharmacol Ther; 2005 Mar; 77(3):170-7. PubMed ID: 15735611
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics and tolerability of a combination of indinavir, lopinavir and ritonavir in multiply pretreated HIV-1 infected adults.
    von Hentig N; Müller A; Rottmann C; Lutz T; Klauke S; Kurowski M; Staszewski S; Harder S
    Eur J Med Res; 2006 Jun; 11(6):236-44. PubMed ID: 16820336
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effect of rifampin administration on the disposition of fexofenadine.
    Hamman MA; Bruce MA; Haehner-Daniels BD; Hall SD
    Clin Pharmacol Ther; 2001 Mar; 69(3):114-21. PubMed ID: 11240975
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Atazanavir and lopinavir with ritonavir alone or in combination: analysis of pharmacokinetic interaction and predictors of drug exposure.
    Di Giambenedetto S; De Luca A; Villani P; Bacarelli A; Ragazzoni E; Regazzi M; Cauda R; Navarra P
    HIV Med; 2008 Apr; 9(4):239-45. PubMed ID: 18366448
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of itraconazole on the pharmacokinetics and pharmacodynamics of fexofenadine in relation to the MDR1 genetic polymorphism.
    Shon JH; Yoon YR; Hong WS; Nguyen PM; Lee SS; Choi YG; Cha IJ; Shin JG
    Clin Pharmacol Ther; 2005 Aug; 78(2):191-201. PubMed ID: 16084853
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Probenecid, but not cystic fibrosis, alters the total and renal clearance of fexofenadine.
    Liu S; Beringer PM; Hidayat L; Rao AP; Louie S; Burckart GJ; Shapiro B
    J Clin Pharmacol; 2008 Aug; 48(8):957-65. PubMed ID: 18511651
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics of atazanavir/ritonavir once daily and lopinavir/ritonavir twice and once daily over 72 h following drug cessation.
    Boffito M; Else L; Back D; Taylor J; Khoo S; Sousa M; Pozniak A; Gazzard B; Moyle G
    Antivir Ther; 2008; 13(7):901-7. PubMed ID: 19043924
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics of lopinavir/ritonavir in HIV/hepatitis C virus-coinfected subjects with hepatic impairment.
    Peng JZ; Pulido F; Causemaker SJ; Li J; Lorenzo A; Cepeda C; García Cabanillas JA; DaSilva B; Brun SC; Arribas J
    J Clin Pharmacol; 2006 Mar; 46(3):265-74. PubMed ID: 16490802
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Drug-drug interaction between itraconazole and the protease inhibitor lopinavir/ritonavir.
    Hills-Nieminen C; Hughes CA; Houston S; Shafran SD
    Ann Pharmacother; 2009 Dec; 43(12):2117-20. PubMed ID: 19934385
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effect of short- and long-term administration of verapamil on the disposition of cytochrome P450 3A and P-glycoprotein substrates.
    Lemma GL; Wang Z; Hamman MA; Zaheer NA; Gorski JC; Hall SD
    Clin Pharmacol Ther; 2006 Mar; 79(3):218-30. PubMed ID: 16513446
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of St John's wort on the pharmacokinetics of fexofenadine.
    Wang Z; Hamman MA; Huang SM; Lesko LJ; Hall SD
    Clin Pharmacol Ther; 2002 Jun; 71(6):414-20. PubMed ID: 12087344
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of the P-glycoprotein inducer carbamazepine on fexofenadine pharmacokinetics.
    Yamada S; Yasui-Furukori N; Akamine Y; Kaneko S; Uno T
    Ther Drug Monit; 2009 Dec; 31(6):764-8. PubMed ID: 19855315
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of atazanavir/ritonavir and lopinavir/ritonavir on glucose uptake and insulin sensitivity: demonstrable differences in vitro and clinically.
    Noor MA; Flint OP; Maa JF; Parker RA
    AIDS; 2006 Sep; 20(14):1813-21. PubMed ID: 16954722
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of acid-reducing agents on the pharmacokinetics of lopinavir/ritonavir and ritonavir-boosted atazanavir.
    Klein CE; Chiu YL; Cai Y; Beck K; King KR; Causemaker SJ; Doan T; Esslinger HU; Podsadecki TJ; Hanna GJ
    J Clin Pharmacol; 2008 May; 48(5):553-62. PubMed ID: 18440920
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.